2.2. Inclusion and Exclusion Criteria
rheumatoid arthritis, abnormal coagulation function, abnormal coagulation, end-stage arthritis, allergic reaction, liver cirrhosis, anaphylactic shock, knee joints, non-OA degenerative, end-stage renal failure
RHEUMATOID ARTHRITIS, ABNORMAL COAGULATION, ALLERGIC REACTION, SEPTIC ARTHRITIS, LIVER CIRRHOSIS, ANAPHYLACTIC SHOCK, END-STAGE RENAL FAILURE, SEVERE ANEMIA
Between September 2017 and August 2019, we consecutively assessed a series of 119 patients who underwent unilateral primary TKA for initial eligibility in this study. The inclusion criteria encompassed adult patients aged 20 to 80 years with end-stage arthritis of the knee joint necessitating TKA. The exclusion criteria for this study were as follows: patients with non-OA degenerative knee joints (e.g., rheumatoid arthritis or septic arthritis), patients with severe anemia (hemoglobin/hematocrit (Hb/Hct) < 12 g/dL/ < 36% before surgery), patients with end-stage renal failure undergoing dialysis treatment, liver cirrhosis leading to abnormal coagulation function (Child A/B/C conditions, platelets < 100,000/µL), patients using any oral anticoagulants or antiplatelets, patients with abnormal coagulation function (INR > 1.5 s), body mass index (BMI) exceeding the standard (35 < BMI < 18), a history of anaphylactic shock or severe allergic reaction to bovine protein (aprotinin), and women who were pregnant and/or breastfeeding.